Information Provided By: 
Fly News Breaks for June 18, 2015
TEVA
Jun 18, 2015 | 12:51 EDT
BMO Capital sees generic competition as imminent after a U.S. Court of Appeals found Teva's patent, which would have extended the exclusivity of Copaxone until September 2015, invalid. The firm, however, points out that the company's updated guidance in April assumed an immediate launch of a Copaxone generic. It keeps a Market Perform rating on Teva.
News For TEVA From the Last 2 Days
There are no results for your query TEVA
